Nolvadex 20mg – 50 Tablets

Tamoxifen Citrate, widely known by its pharmaceutical brand name Nolvadex, is a selective estrogen receptor modulator (SERM) with one of the most extensively documented clinical histories of any pharmaceutical compound. FDA approved since 1977 for breast cancer treatment and remaining among the most prescribed and researched SERMs in oncology and endocrinology literature across nearly five decades of continuous clinical investigation. F40 Biotech’s formulation delivers 20mg per tablet in a 50 count format, consistent with the concentration most commonly referenced in both oncological and HPG axis restoration research literature.

Tamoxifen’s SERM activity is defined by its tissue selective estrogen receptor interaction, acting as an estrogen antagonist in breast tissue and the hypothalamic pituitary axis while exerting partial estrogen agonist activity in other tissue sites including bone, liver, and endometrial tissue. This tissue selectivity is the pharmacological characteristic that distinguishes Tamoxifen’s research profile from Clomiphene and Enclomiphene within CSD’s SERM range. Where Clomiphene’s HPG axis stimulation is driven primarily by hypothalamic estrogen antagonism, Tamoxifen’s antagonist activity at the pituitary level is particularly well documented. Blocking estrogen’s suppressive effect on gonadotropin secretion through a slightly different receptor interaction profile that has generated comparative SERM research into the differential HPG axis stimulation characteristics of the two compounds at equivalent doses.

Tamoxifen’s metabolic pathway is a research relevant pharmacological characteristic that distinguishes it from other SERMs. Tamoxifen is a prodrug, requiring hepatic CYP2D6 enzyme conversion to its active metabolite Endoxifen, which carries substantially higher estrogen receptor binding affinity than the parent compound. This CYP2D6 dependent activation makes Tamoxifen research particularly relevant in studies examining pharmacogenomic variability, drug interaction effects on SERM activity, and the relationship between metabolizer status and clinical outcomes. Research dimension that single isomer SERMs like Enclomiphene and direct acting compounds like Anastrozole do not share.

F40 Biotech formulations are stocked by Canada Steroid Depot following the same rigorous third party lab verification process applied to every product in our range. Each batch is tested for concentration accuracy and purity before being made available, with COA documentation available on request. CSD stocks a comprehensive SERM and estrogen management range: Tamoxifen, Clomiphene, Enclomiphene, and Anastrozole; covering selective receptor modulation, pure isomer HPG stimulation, and aromatase inhibition from a single verified Canadian supplier for complete estrogen regulation research coverage. All orders ship discreetly across Canada in plain, unmarked packaging with no identifying information on the exterior.

Store in a cool, dry place away from direct light and heat. Intended for research purposes only.

Commonly researched alongside Clomiphene and HCG in comparative SERM and HPG axis restoration studies. Browse CSD’s full PCT range for complete sourcing.